Navigation Links
Ambry Genetics Announces the Addition of Illumina HiSeq 2000 and First 510(K) Approved BeadXpress® to Its Sequencing and Genotyping Capabilities
Date:8/25/2010

ALISO VIEJO, Calif., Aug. 25 /PRNewswire/ -- Ambry Genetics, a global leader in genomic services, announced today that it has acquired the Illumina HiSeq 2000 Next Generation Sequencing System as well as received the first 510(K) approved Illumina BeadXpress Genotyping System. Ambry Genetics has been an early adapter of Illumina systems since late 2007 and has extensive experience as a Certified Service Provider. A team of scientists routinely process libraries for all available applications ranging from small RNAs to whole genome DNA sequencing.  Ambry has gained a solid reputation for quality data and service as well as flexibility in customizing projects to meet the specific needs of researchers.  

(Logo:  http://photos.prnewswire.com/prnh/20090428/LA06744LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090428/LA06744LOGO)

The addition of the HiSeq 2000 will allow Ambry Genetics to run large projects for its customers while saving costs and providing the fastest turn-around times for sequencing. Ambry Genetics has an experienced bioinformatics team that can generate custom reports, providing flexible and results-driven informatics for sequencing projects. In addition to sequencing, Ambry Genetics currently offers diverse options for researchers interested in sequence capture / target enrichment by utilizing Agilent Technologies SureSelect, RainDance Technologies and Roche Nimblegen.

The new Illumina BeadXpress adds high-throughput genotyping capabilities to Ambry Genetics' existing line of services. The BeadXpress uses GoldenGate assays on the VeraCode technology which provides researchers with accuracy, flexibility and scalability for their projects.  The system supports high level variant plexing and can process up to 96 samples per plate, which can dramatically reduce the cost of genotyping assays and deliver rapid turn-around times.

About Ambry Genetics -Ambry Genetics is a CAP-accredited and CLIA-certified commercial clinical laboratory headquartered in Aliso Viejo, California. Since the company's inception in 2000, it has become a leader in providing genetic services focused on clinical diagnostics and genomic services. Ambry has built a solid reputation for unparalleled service, and has been at the forefront of applying new technologies to the clinical molecular diagnostics market and advancements in disease research. To learn more about testing and services available through Ambry, visit www.ambrygen.com


'/>"/>
SOURCE Ambry Genetics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambry Genetics Announces Launch of Their StemArray(TM) Product and Services for High Resolution Characterization of Human Stem Cells
2. Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects
3. Ambry Genetics and RainDance Technologies Announce Partnership for Diagnostics and Genomics Services Utilizing the RDT 1000 for Sequence Enrichment and Targeted Resequencing Validation
4. Ambry Genetics Introduces AmbryScreen(TM), a Genetic Test Screening for Some of the Most Common and Severe Genetic Disorders Affecting Newborns.
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Genetics Determine Optimal Drug Dose of Common Anticoagulant
8. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
9. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
10. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
11. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 Allergy Diagnostics Market: Scope and ... that are used to determine the presence of ... drugs etc. in the samples by determining the ... The report on global allergy diagnostics market, analyzes ... The report consists of an executive summary that ...
(Date:12/8/2016)... , Dec 8, 2016 Research and Markets has ... report to their offering. ... This report analyzes the worldwide markets for Endodontic ... Canada , Japan , Europe ... and Rest of World. Annual estimates and forecasts are provided for ...
(Date:12/8/2016)... Mederi Therapeutics Inc . anunciou aprovação regulatória, pela CFDA, e lançamento de produto ... gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... performed and broadcast during the Chinese Congress of Digestive Endoscopy, by Professor Jun ... , , ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... 2016 , ... The Justin Veatch Fund announced Thursday that ... film Whispering Spirits and its discussion guide for use by all of ... in the war against teen drug abuse. NCADD is the oldest anti-addiction advocacy ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name Medical Center ... NY, on December 3rd, to benefit Holy Name Medical Center's programs and services. ... raised over $1 million - the largest event in the Center's history, both ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... become Quality Insights beginning January 1, 2017. The name change aligns the ... to measuring and improving health care quality. , “We are very proud of ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate that ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand ... “What’s In Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety ... dental implant and prosthetic market in the U.S. is projected to reach $6.4 billion ...
Breaking Medicine News(10 mins):